News Rob Bent News Rob Bent

7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.

Read More
News Rob Bent News Rob Bent

7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma

7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.

Read More
News Rob Bent News Rob Bent

IMMUNE ACTIVATORS – Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.

Read More